CMA mediates the ARPI stress response in prostate cancer, promoting ARPI treatment resistance

被引：0
|
作者：
Nikesitch, Nicholas [1 ,2 ]
Beraldi, Eliana [1 ]
Zhang, Fan [1 ]
Adomat, Hans [1 ]
Bell, Robert [1 ]
Wells, Christopher [1 ]
Saxena, Neetu [1 ]
Somasekharan, Syam Prakash [1 ]
Gleave, Andmartin [1 ,2 ]
机构：
[1] Vancouver Prostate Ctr, Vancouver, BC, Canada
[2] Univ British Columbia, Vancouver, BC, Canada
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
158
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [1] CMA mediates resistance to androgen inhibitors in prostate cancer
    Masone, Maria Chiara
    NATURE REVIEWS UROLOGY, 2023, 20 (03) : 129 - 129
  • [2] CMA mediates resistance to androgen inhibitors in prostate cancer
    Maria Chiara Masone
    Nature Reviews Urology, 2023, 20 : 129 - 129
  • [3] Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI
    Watson, Alexander S.
    Gagnon, Richard
    Batuyong, Eugene
    Alimohamed, Nimira
    Lee-Ying, Richard
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : 496.e1 - 496.e9
  • [4] Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease
    Schoen, Martin W.
    Etzioni, Ruth Douglas
    Luo, Suhong
    Candelieri, Danielle
    Fedele, Nicholas
    Baxi, Priya
    Pickett, Carley
    Riekhof, Forest
    Ingram, Kara
    Karunanandaa, Krishny
    Govindan, Srinivas
    Cheranda, Nina
    Knoche, Eric Marshall
    Montgomery, Robert Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] CMA mediates resistance in breast cancer models
    Alessia Lo Dico
    C. Martelli
    F. Corsi
    D. Porro
    L. Ottobrini
    G. Bertoli
    Cancer Cell International, 23
  • [6] CMA mediates resistance in breast cancer models
    Lo Dico, Alessia
    Martelli, C.
    Corsi, F.
    Porro, D.
    Ottobrini, L.
    Bertoli, G.
    CANCER CELL INTERNATIONAL, 2023, 23 (01)
  • [7] Predictive genomic biomarkers in non-metastatic castration resistant prostate cancer (nmCRPC) treated with androgen receptor pathway inhibitors (ARPi)
    Gagnon, R.
    El Hallani, S. E.
    Lee-Ying, R.
    Kolinsky, M. P.
    Khalaf, D. J.
    Cook, S.
    Vasquez, C.
    Samuel, D.
    Lewis, J. D.
    Faridi, R. M.
    Borkar, M.
    Heng, D. Y. C.
    Alimohamed, N.
    Ruether, J. D.
    Gotto, G. T.
    Fairey, A.
    Bismar, T. A.
    Yip, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S647 - S647
  • [8] Identifying patient profiles and mapping treatment journeys of ARPI-treated, taxane-naive patients with metastatic prostate cancer across three countries in a digital patient survey
    O'Sullivan, Joe M.
    Lehmann, Reiner
    Sievert, Henning
    Allen, Stephen
    Carl, Ernst-Guenther
    Wolinsky, Howard
    Poschenrieder, Andreas
    Mirante, Osvaldo
    Morgans, Alicia K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 56 - 56
  • [9] NPTX1 IS A NOVEL SERUM BIOMARKER INDUCED BY ARPI TREATED PROSTATE CANCER AND ENRICHED IN LINEAGE PLASTICITY WITH BRN2 HIGH
    Namekawa, Takeshi
    Scurll, Joshua
    Kobelev, Maxim
    Ganguli, Dwaipayan
    Sivak, Olena
    Gleave, Martin
    Corey, Eva
    Morrissey, Colm
    Zoubeidi, Amina
    JOURNAL OF UROLOGY, 2023, 209 : E277 - E278
  • [10] PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?
    Shimomura, Tatsuya
    Otsuka, Naoki
    Urabe, Fumihiko
    Muramoto, Katsuki
    Yanagisawa, Takafumi
    Fukuokaya, Wataru
    Mori, Keiichiro
    Tashiro, Kojiro
    Katsumi, Kota
    Takahashi, Hidetsugu
    Yoshihara, Kentaro
    Miyajima, Keiichiro
    Imai, Yu
    Iwatani, Kosuke
    Kayano, Sotaro
    Igarashi, Taro
    Murakami, Masaya
    Tsuzuki, Shunsuke
    Yamada, Hiroki
    Miki, Jun
    Kimura, Takahiro
    PROSTATE, 2025,
12345